Form 4: Relay Therapeutics Officer Sells Shares for Tax Obligations
Insider Transaction Report
Relay Therapeutics' Chief Corporate Development Officer, Peter Rahmer, sold 17,083 shares of common stock across two transactions to cover income tax withholding obligations related to RSU vesting.
Summary
- Peter Rahmer, Chief Corporate Development Officer of Relay Therapeutics, Inc. (RLAY), reported two sales of common stock.
- On July 28, 2025, 1,359 shares were sold at $3.74 per share. This sale covered tax obligations from the vesting of 5,506 restricted stock units (RSUs) on July 27, 2025.
- On July 29, 2025, an additional 15,724 shares were sold at $3.68 per share. This sale covered tax obligations from the vesting of 42,393 RSUs on July 28, 2025.
- The sales were non-discretionary and conducted in accordance with the Issuer's policies regarding the vesting of RSUs.
- Following these transactions, Peter Rahmer beneficially owns 377,998 shares, which includes 156,816 shares underlying RSUs.
Sentiment
Score: 5
Explanation: The filing reports routine, non-discretionary sales of shares by an officer to cover tax obligations upon RSU vesting. This type of transaction is neutral in sentiment as it does not indicate a change in the officer's view of the company's prospects or a discretionary divestment.
Future Outlook
NA
Industry Context
This filing represents a routine insider transaction for tax withholding purposes, common across all industries when restricted stock units vest. It does not reflect broader industry trends or competitive positioning.
Stakeholder Impact
- Minimal impact on shareholders as the sales are non-discretionary and for tax purposes, not indicative of a change in confidence.
- No direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 07/27/2025 | Vesting date for 5,506 restricted stock units (RSUs) for Peter Rahmer. |
| 07/28/2025 | Transaction date for the sale of 1,359 shares of common stock by Peter Rahmer at $3.74 per share to cover tax obligations. |
| 07/28/2025 | Vesting date for 42,393 restricted stock units (RSUs) for Peter Rahmer. |
| 07/29/2025 | Transaction date for the sale of 15,724 shares of common stock by Peter Rahmer at $3.68 per share to cover tax obligations. |
| 07/30/2025 | Signature date of the Form 4 filing by Brian Adams, as Attorney-in-Fact for Peter Rahmer. |
Recommendation
holdThe reported transactions are non-discretionary sales by an officer to cover tax withholding obligations upon the vesting of restricted stock units. This is a routine event and does not reflect a change in the officer's investment thesis or confidence in the company. Therefore, it provides no new information that would warrant a change in investment recommendation; a 'hold' stance is appropriate unless other fundamental factors change.
Keywords
Relay Therapeutics, RLAY, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, RSU Vesting, Tax Withholding, Officer Transaction, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.